Synergistic antiproliferative activity of tamoxifen and docetaxel on three oestrogen receptor-negative cancer cell lines is mediated by the induction of apoptosis

British Journal of Cancer

Volumn 75, Issue 6, 1997, Pages 884-891

  Ferlini, C ^a,b   Scambia, G ^a,b   Distefano, M ^a,b   Filippini, P ^a,b   Isola, G ^a,c   Riva, A ^a,c   Bombardelli, E ^a,c   Fattorossi, A ^a,b   Benedetti Panici, P ^b,c   Mancuso, S ^a,c  

^a Laboratory of Antineoplastic Pharmacology   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c Lndena SpA Milan Italy   (Italy)

Author keywords

Apoptosis; Cell cycle; Docetaxel; Tamoxifen

Indexed keywords

ANTIESTROGEN; ANTINEOPLASTIC AGENT; DOCETAXEL; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DRUG POTENTIATION; FLOW CYTOMETRY; GROWTH INHIBITION; PRIORITY JOURNAL;

EID: 8044226014     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.156     Document Type: Article

References (26)

1. Bardon S, Vignon F, Montcourrier P and Rochefort H (1987) Steroid receptormediated cytotoxicity of an antioestrogen and an antiprogestin in breast cancer cells. Cancer Res 47: 1441-1448
2. Berenbaum KC (1981) Criteria for analyzing interaction between biologically active agents. Adv Cancer Res 25: 269-335
3. Berman E, Adams M, Duigou-Ostendorf R, Godfrey L, Clarkson B and Andreef M (1991) Effect of tamo.xifen on cell lines displaying the multidrug-resistant phenotype. Blood 77: 818-825
4. Bhalla K, Huang Y, Tang C, Self S, Ray S, Mahoney ME, Ponnathpur V, Tourkina E, Ibrado AM, Bullock G and Willingham MC (1994) Characterization of a human myeloid leukemia cell line higly resistant to taxol. Leukemia 8: 465-175
5. Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P and Traganos F (1992) Features of apoptotic cells measured by flow cytometry Cytometry 13: 795-808
6. De Vmcenzo R, Scambia G, Benedetti Panici P, Fattorossi A, Bonanno G, Ferlini C, Isola G, Pernisco S and Mancuso S (1996) Modulatory effect of tamoxifen and ICI 182,780 on adryamicin resistance in MCF-7 human breast cancer cells. Int J Cancer
7. Distefano M, Scambia G, Ferlini C, Gaggini C, De Vmcenzo R, Riva A, Bombardelli E, Benedetti Pomiei P, Momenso S (1997) Antiproliferative activity of a new class of taxanes (14-hydroxy 10-deacetylbacestin III derivatives) on MDR-positive human cancer cells. (Submitted for publication)
8. Ferlini C, Di Cesare S, Rainaldi G, Malorni W, Samoggia P, Biselli R and Fattorossi A (1996) A flow cytometric analysis of the early phases of apoptosis by cellular and nuclear techniques. Cytomelry 24: 106-115
9. Hofmann J, DopplerW, Jakob A, Rösch L, Überall F and Grunicke HH (1988) Enhanncement of the antiproliferative effect of cis-diamminechloroplatinum (II) and nitrogen mustard by inhibitors of protein kinase C. Int J Cancer 42: 382-389
10. Issandou M, Faucher C, Bayard F and Darbon JM (1990) Opposite effects of tamoxifen on in vitro protein kinase C activity and endogenous protein phosphorylation in intact MCF-7 cells. Cancer Res 50: 5845-5850
11. Jordan VC and Murphy CS (1990) Endocrine pharmacology of antioestrogens as antitumour agents. Endocrine Rev 11: 5780-6180
12. Leonessa F, Jacobson M, Boyle B, Lippman J, Mcgarvey M and Clarke R (1994) Effect of tamoxifen on the mukidrug-resistant phenotype in human breast cancer cells: isobologram, drug accumulation and Mr 170 000 glycoprotein (gp 170) binding studies. Cancer Res 54: 441-447
13. Lien EA, Solheim E and Ueland PM (1991) Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res 51:4837-4844
14. Lopes MCF, Vale MGP and Caravalho AP (1990) Ca-dependent binding of tamoxifen to calmodulin isolated from bovine brain. Cancer Res 50: 2753-2758
15. Mastropaolo D, Canerman A, Luo Y, Brayer GD and Camerman N (1995) Crystal and molecular structure of paclitaxel (taxol). Proc Natl Acad Sei USA 92: 6920-6924
16. McClay EF, Mastrangelo MJ, Sprandio DJ, Bellet RE and Herd D (1989) The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. Cancer 63: 1292-1295
17. Perry RR, Kang Y and Greaves BR (1995) Relationship between tamoxifen-induced transforming growth factor betal expression, cytostasis and apoptosis in human breast cancer cells. Br J Cancer 72: 1441-1446
18. Ramu A, Glaubiger D and Fuks Z (1984) Reversal of acquired resistance to doxorubicin in P388 murine leukaemia cells by tamoxifen and triparanol analogues. Cancer Res 44:4392-4397
19. Scambia G, Ranelletti FO, Benedetti Panici P, Piantelli M, Bonanno G, De Vmcenzo R, Ferrandina G, Pierelli L, Capelli A and Mancuso S (1991) Quercetin inhibits the growth of a multidrug-resistant estrogen receptor negative MCF-7 human breast cancer cell line expressing type II estrogen binding sites. Cancer Chemolher Pharmacol 28: 255-258
20. Scambia G, Ranelletti FO, Benedetti Panici P, Piantelli M, De Vmcenzo R, Bonanno G, Ferrandina G, Isola G and Mancuso S (1992) Synergistic antiproliferative activity of tamoxifen and cisplatin on primary ovarian tumours. Eur J Cancer 11:1885-1889
21. Scambia G, Ranelletti FO, Benedetti Panici P, De Vmcenzo R, Bonanno G, Ferrandina G, Piantelli M, Bussa D, Rumi C, Cianfriglia M and Mancuso S (1994) Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast cancer cell line: P-glycoprotein as a possible target. Cancer Chemother Pharmacol 34: 459-464
22. Schiff PB, Fant J and Horwitz SB (1979) Promotion of microtubule assembly m vitro by taxol. Nature 277: 665-667
23. Sclichenmyer WJ and Von Hoff D (1991) Taxol: a new and effective anti-cancer drug. Anti-Cancer Drugs 2: 519-530
24. Trump DL, Smith DC, Ellis PG, Rogers MP, Schold SC, Winer EP, Panella TJ, Jordan VC and Fine RL (1992) High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Insl 84: 1811-1816
25. Warn AM, Huovinen RL, Laine AM, Martikainen PM and Harkonen K (1993) Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro. J Nail Cancer Inst 85: 1412-1418
26. Wyllie AH (1980) Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonucleases activation. Nature 245: 255